Comparison Overview

AUROBINDO PHARMA LTD

VS

Teva Pharmaceuticals

AUROBINDO PHARMA LTD

Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District,, Hyderabad, Telangana, IN, 500032
Last Update: 2025-12-17
Between 750 and 799

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 14,616
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Teva Pharmaceuticals

124 Dvora hanevi'a, Tel-Aviv, undefined, 6944020, IL
Last Update: 2025-12-17
Between 800 and 849

At Teva, we're proud to be a different kind of global pharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, our commitment to bettering health has never wavered. Every day, we challenge ourselves to push the boundaries of science, discover life-changing treatments, and deliver quality medicines. If patients have a need, we’re already working to address it. Because here, we are all in for better health. Learn more at www.tevapharm.com. Please note that adverse effects for any of our products should be reported to: [email protected] Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 29,653
Subsidiaries: 5
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/aurobindopharma.jpeg
AUROBINDO PHARMA LTD
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/teva-pharmaceuticals.jpeg
Teva Pharmaceuticals
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
AUROBINDO PHARMA LTD
100%
Compliance Rate
0/4 Standards Verified
Teva Pharmaceuticals
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for AUROBINDO PHARMA LTD in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Teva Pharmaceuticals in 2025.

Incident History — AUROBINDO PHARMA LTD (X = Date, Y = Severity)

AUROBINDO PHARMA LTD cyber incidents detection timeline including parent company and subsidiaries

Incident History — Teva Pharmaceuticals (X = Date, Y = Severity)

Teva Pharmaceuticals cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/aurobindopharma.jpeg
AUROBINDO PHARMA LTD
Incidents

No Incident

https://images.rankiteo.com/companyimages/teva-pharmaceuticals.jpeg
Teva Pharmaceuticals
Incidents

No Incident

FAQ

Teva Pharmaceuticals company demonstrates a stronger AI Cybersecurity Score compared to AUROBINDO PHARMA LTD company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Teva Pharmaceuticals company has disclosed a higher number of cyber incidents compared to AUROBINDO PHARMA LTD company.

In the current year, Teva Pharmaceuticals company and AUROBINDO PHARMA LTD company have not reported any cyber incidents.

Neither Teva Pharmaceuticals company nor AUROBINDO PHARMA LTD company has reported experiencing a ransomware attack publicly.

Neither Teva Pharmaceuticals company nor AUROBINDO PHARMA LTD company has reported experiencing a data breach publicly.

Neither Teva Pharmaceuticals company nor AUROBINDO PHARMA LTD company has reported experiencing targeted cyberattacks publicly.

Neither AUROBINDO PHARMA LTD company nor Teva Pharmaceuticals company has reported experiencing or disclosing vulnerabilities publicly.

Neither AUROBINDO PHARMA LTD nor Teva Pharmaceuticals holds any compliance certifications.

Neither company holds any compliance certifications.

Teva Pharmaceuticals company has more subsidiaries worldwide compared to AUROBINDO PHARMA LTD company.

Teva Pharmaceuticals company employs more people globally than AUROBINDO PHARMA LTD company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither AUROBINDO PHARMA LTD nor Teva Pharmaceuticals holds SOC 2 Type 1 certification.

Neither AUROBINDO PHARMA LTD nor Teva Pharmaceuticals holds SOC 2 Type 2 certification.

Neither AUROBINDO PHARMA LTD nor Teva Pharmaceuticals holds ISO 27001 certification.

Neither AUROBINDO PHARMA LTD nor Teva Pharmaceuticals holds PCI DSS certification.

Neither AUROBINDO PHARMA LTD nor Teva Pharmaceuticals holds HIPAA certification.

Neither AUROBINDO PHARMA LTD nor Teva Pharmaceuticals holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

A vulnerability has been found in SeaCMS up to 13.3. The affected element is an unknown function of the file js/player/dmplayer/dmku/class/mysqli.class.php. Such manipulation of the argument page/limit leads to sql injection. The attack can be executed remotely. The exploit has been disclosed to the public and may be used.

Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability in HappyDevs TempTool allows Stored XSS.This issue affects TempTool: from n/a through 1.3.1.

Risk Information
cvss3
Base: 6.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:L
Description

Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability in Tormorten WP Microdata allows Stored XSS.This issue affects WP Microdata: from n/a through 1.0.

Risk Information
cvss3
Base: 6.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:L
Description

Exposure of Sensitive System Information to an Unauthorized Control Sphere vulnerability in HappyDevs TempTool allows Retrieve Embedded Sensitive Data.This issue affects TempTool: from n/a through 1.3.1.

Risk Information
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N
Description

A vulnerability has been found in Tenda FH1201 1.2.0.14(408). Affected is the function sprintf of the file /goform/SetIpBind. Such manipulation of the argument page leads to stack-based buffer overflow. The attack may be performed from remote. The exploit has been disclosed to the public and may be used.

Risk Information
cvss2
Base: 9.0
Severity: LOW
AV:N/AC:L/Au:S/C:C/I:C/A:C
cvss3
Base: 8.8
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
cvss4
Base: 7.4
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X